{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:10:24Z","timestamp":1788221424347,"version":"build-2803163510"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Gastric metastasis of breast cancer is rare, and clinical data on its treatment and prognosis are limited at present. Herein, we report a case of gastric metastasis arising from invasive ductal and mucinous carcinoma of the breast and review the literature. A 51-year-old woman was diagnosed with infiltrating and mucinous carcinoma of the right breast accompanied by ipsilateral axillary lymph node and subclavian lymph node metastases. The molecular subtype was luminal A, and the clinical stage was T4bN3M0. The patient first received 5 cycles of neoadjuvant chemotherapy, and the treatment efficacy was stable. After 3 months of treatment with abemaciclib combined with exemestane, the tumors did not significantly reduce in size. The patient underwent surgery on February 23, 2023. The postoperative pathological examination revealed Miller Payne system grade 3 (G3). Cancer metastasis (14\/20) was observed in the axillary lymph nodes, and the immunohistochemical results were as follows: ER (++, 90%), PR (+, 2%), HER-2 (3+), and Ki-67 (20%). The adjuvant therapy used was exemestane combined with trastuzumab and pertuzumab. Gastric metastasis was observed 10 months after surgery. The pathological examination revealed focal atypical cell nests with disordered arrangements, indicating malignant lesions (cancer). The immunohistochemical results were as follows: GATA3 (+), ER (++, 90%), PR (-), and HER-2 (1+). In the late stage, first-line treatment with dalpiciclib and fulvestrant was administered, and liver metastasis occurred 10 months thereafter. T-DXd treatment was subsequently administered, and the patient is currently undergoing clinical follow-up. This case highlights the possibility of gastric metastasis when gastrointestinal symptoms occur in patients with a history of breast cancer.<\/jats:p>","DOI":"10.3389\/fonc.2025.1576874","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:26:21Z","timestamp":1755753981000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Gastric metastasis arising from invasive ductal and mucinous carcinoma of the breast: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhidong","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101719","article-title":"Radiomics in\u2002breast\u2002cancer: Current advances and future directions","volume":"5","author":"Qi","year":"2024","journal-title":"Cell Rep Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010258","article-title":"Gastric\u2002metastasis\u2002from\u2002invasive\u2002lobular\u2002breast cancer, mimicking primary\u2002gastric\u2002cancer: A case report","volume":"97","author":"Kim","year":"2018","journal-title":"Med (Baltimore)."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2023.10.002","article-title":"Pathological response in\u2002mucinous\u2002carcinoma\u2002of\u2002breast\u2002after neoadjuvant therapy-a multi-institutional study","volume":"142","author":"Zhan","year":"2023","journal-title":"Hum Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/03000605241233988","article-title":"Gastric metastasis from breast cancer: five cases and a single-institutional review","volume":"52","author":"Cheng","year":"2024","journal-title":"J Int Med Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16553","article-title":"Gastric and bone metastases arising from invasive lobular carcinoma with ductal carcinoma occurring in one breast synchronously","volume":"43","author":"Namikawa","year":"2023","journal-title":"Anticancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001201)89:11<2214::AID-CNCR9>3.0.CO;2-D","article-title":"Clinical presentation, endoscopic features, and treatment of\u2002gastric\u2002metastases\u2002from breast carcinoma","volume":"89","author":"Taal","year":"2000","journal-title":"Cancer."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5107(92)70377-0","article-title":"The spectrum of gastrointestinal\u2002metastases\u2002of breast carcinoma: I.\u2002Stomach","volume":"38","author":"Taal","year":"1992","journal-title":"Gastrointest Endosc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.08.007","article-title":"Wide metastatic spreading in infiltrating lobular carcinoma of the breast","volume":"40","author":"Ferlicot","year":"2004","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-017-0705-7","article-title":"Infiltrating lobular breast cancer presenting as isolated gastric metastasis: a case report","volume":"9","author":"Bushan","year":"2017","journal-title":"Indian J Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02062.x","article-title":"Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma","volume":"46","author":"Van Velthuysen","year":"2005","journal-title":"Histopathology."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-Receptor-Positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS:a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104305","article-title":"Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor\u2002receptor\u20022-low\/positive advanced breast cancer:A meta-analysis of randomized controlled trials","volume":"196","author":"Ma","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1576874\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:26:21Z","timestamp":1755753981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1576874\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":16,"alternative-id":["10.3389\/fonc.2025.1576874"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1576874","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"article-number":"1576874"}}